Oral curcumin in elective abdominal aortic aneurysm repair: A multicentre randomized controlled trial

Amit X. Garg, P. J. Devereaux, Andrew Hill, Manish Sood, Bharat Aggarwal, Luc Dubois, Swapnil Hiremath, Randolph Guzman, Vikram Iyer, Matthew James, Eric McArthur, Louise Moist, George Ouellet, Chirag Parikh, Virginia Schumann, Sumit Sharan, Heather Thiessen Philbrook, Sheldon Tobe, Ron Wald, Michael WalshMatthew Weir, Neesh Pannu

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Curcumin, a popular herbal supplement from the plant turmeric, has prevented ischemic reperfusion and toxin-induced injury in many animal studies and a singlecentre randomized human trial. We sought to test whether perioperative oral curcumin (compared with plac ebo) affects the inflammatory response and risk of postrepair complications after elective abdominal aortic aneurysm repair in humans. METHODS: We conducted a parallelgroup, randomized, placebo-controlled trial of patients from 10 hospitals in Canada who were scheduled to undergo elective repair of an unruptured abdominal aortic aneurysm (November 2011 to November 2014). Patients in the treatment group received perioperative oral curcumin (2000-mg doses 8 times over 4 d). Patients, health care providers and local research staff were unaware of the treatment assignment. The primary outcomes were median concentrations of 4 biomarkers indicating injury and inflammation (postoperative urine interleukin-18 and perioperative rise in serum creatinine, plasma N-terminal pro-B-type natriuretic peptide and plasma highsensitivity C-reactive protein). RESULTS: Baseline characteristics were similar in the 2 groups (606 patients overall; median age 76 yr). More than 85% of patients in each group took more than 80% of their scheduled capsules. Neither curcumin nor placebo significantly affected any of the 4 biomarkers (p > 0.05 for all comparisons). Regarding the secondary outcomes, there was a higher risk of acute kidney injury with curcumin than with placebo (17% v. 10%, p = 0.01), but no between-group difference in the median length of hospital stay (5 v. 5 days, p > 0.9) or the risk of clinical events (9% v. 9%, p = 0.9). INTERPRETATION: Curcumin had no beneficial effects when used in elective abdominal aortic aneurysm repair. These findings emphasize the importance of testing turmeric and curcumin before espousing their health benefits, as is currently done in the popular media.

Original languageEnglish (US)
Pages (from-to)E1273-E1280
JournalCMAJ
Volume190
Issue number43
DOIs
StatePublished - Oct 29 2018

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Oral curcumin in elective abdominal aortic aneurysm repair: A multicentre randomized controlled trial'. Together they form a unique fingerprint.

  • Cite this

    Garg, A. X., Devereaux, P. J., Hill, A., Sood, M., Aggarwal, B., Dubois, L., Hiremath, S., Guzman, R., Iyer, V., James, M., McArthur, E., Moist, L., Ouellet, G., Parikh, C., Schumann, V., Sharan, S., Thiessen Philbrook, H., Tobe, S., Wald, R., ... Pannu, N. (2018). Oral curcumin in elective abdominal aortic aneurysm repair: A multicentre randomized controlled trial. CMAJ, 190(43), E1273-E1280. https://doi.org/10.1503/cmaj.180510